| Bioactivity | BRG1-IN-1 (Compound 11d) is a potent inhibitor of BRG1. BRG1-IN-1 shows better efficacy than PFI-3 in sensitizing GBM cells to the antiproliferative and cell death inducing effects of Temozolomide in vitro. BRG1-IN-1 enhances the inhibitor effect of Temozolomide on the growth of subcutaneous GBM tumors[1]. |
| Name | BRG1-IN-1 |
| CAS | 2616813-99-9 |
| Formula | C20H19FN2O |
| Molar Mass | 322.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. He Y, et al. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells. Bioorg Med Chem. 2022 Jan 1;53:116533. |
BRG1-IN-1
CAS: 2616813-99-9 F: C20H19FN2O W: 322.38
BRG1-IN-1 (Compound 11d) is a potent inhibitor of BRG1. BRG1-IN-1 shows better efficacy than PFI-3 in sensitizing GBM ce
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.